about
Italian guidelines for primary headaches: 2012 revised versionWhere is dihydroergotamine mesylate in the changing landscape of migraine therapy?Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.Use of dihydroergotamine (DHE) should be restricted to no more than twice a week.Considerations for management of migraine symptoms in the primary care setting.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dihydroergotamine: role in the treatment of migraine.
@en
Dihydroergotamine: role in the treatment of migraine.
@nl
type
label
Dihydroergotamine: role in the treatment of migraine.
@en
Dihydroergotamine: role in the treatment of migraine.
@nl
prefLabel
Dihydroergotamine: role in the treatment of migraine.
@en
Dihydroergotamine: role in the treatment of migraine.
@nl
P2860
P1476
Dihydroergotamine: role in the treatment of migraine.
@en
P2860
P304
P356
10.1517/17425250903164211
P407
P577
2009-09-01T00:00:00Z